Post-Viral Fatigue Syndrome Clinical Trial
Official title:
The Use of a Rehabilitation Robot in Patients With Post-COVID-19 Fatigue Syndrome
The aim of the study is to compare the effectiveness of two models of rehabilitation: - traditional neurological rehabilitation, and - neurological rehabilitation combined with a rehabilitation robot (Luna by EGZOTech). An additional goal is to test the qualitative diagnostic reference using the surface electromyogram of the Luna robot (certified as a Medical Device) for functional diagnostics based on standardized clinical tests.
Status | Recruiting |
Enrollment | 80 |
Est. completion date | December 31, 2022 |
Est. primary completion date | July 31, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A and older |
Eligibility | Inclusion Criteria: - patients discharged from Intensive Care Units after undergone ventilator therapy due to COVID-19 Exclusion Criteria: - active medical condition (infections; tumors; rheumatological, metabolic, endocrine, autoimmunological, cardiovascular diseases) - bipolar disorder - dementia - nutritional disorders - addiction to alcohol or psychoactive substances - severe obesity - overtraining |
Country | Name | City | State |
---|---|---|---|
Poland | Poznan University of Medical Sciences | Poznan |
Lead Sponsor | Collaborator |
---|---|
Poznan University of Medical Sciences | EGZOTech sp. z o.o., Szpital Wojewódzki w Poznaniu |
Poland,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in muscle fatigue assessment | Raw robot measurement data (isometric contraction of the muscle for 60 s - biceps, quadriceps) | Baseline, after 3 and after 8 weeks | |
Primary | Change in isokinetic muscle force | Raw robot measurement data (5 repetitions during measurement with LUNA) | Baseline, after 3 and after 8 weeks | |
Secondary | Change in functional physical ability 1 | Functional Independence Measure | Baseline, after 3 and after 8 weeks | |
Secondary | Change in functional physical ability 2 | Barthel Index | Baseline, after 3 and after 8 weeks | |
Secondary | Change in functional physical ability 3 | Berg Balance Test | Baseline, after 3 and after 8 weeks | |
Secondary | Change in functional physical ability 4 | Short Physical Performance Battery | Baseline, after 3 and after 8 weeks | |
Secondary | Change in cognitive ability 1 | Addenbrooke's Cognitive Examination (ACE-III) | Baseline, after 3 and after 8 weeks | |
Secondary | Change in cognitive ability 2 | Montreal Cognitive Assessment | Baseline, after 3 and after 8 weeks | |
Secondary | Change in the quality of life | WHOQOL | Baseline, after 3 and after 8 weeks | |
Secondary | Change in depressive symptoms | Beck's Depression Inventory | Baseline, after 3 and after 8 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05430152 -
Low-dose Naltrexone for Post-COVID Fatigue Syndrome
|
Phase 2 | |
Recruiting |
NCT04705831 -
Study to Evaluate the Benefit of RUCONEST in Improving Neurological Symptoms in Post COVID-19 Infection
|
Phase 4 |